B PURUI
LIVE

Serial Number

79143546

Owner

Zhejiang Pure Pharmaceutical Co., Ltd.

Attorney

John Alumit

Filing Date

Nov 28, 2013

Add to watchlist:

No watchlists yet
View on USPTO

B PURUI Trademark

Serial Number: 79143546 • Registration: 4634904

B PURUI is a trademark filed by Zhejiang Pure Pharmaceutical Co., Ltd. on November 28, 2013. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Zhejiang Pure Pharmaceutical Co., Ltd.

Modern Industrial Convergence Zone,

Entity Type: 99

Xianju Pure Pharmaceutical Co., Ltd

Modern Industrial Convergence Zone
Xianju, Zhejiang , CN

Entity Type: 99

Trademark Details

Filing Date

November 28, 2013

Registration Date

November 11, 2014

Published for Opposition

August 26, 2014

Cancellation Date

November 27, 2023

Goods & Services

Pharmaceutical preparations in injection, tablet, and liquid for treating allergic rhinitis and asthma, diabetes, skin disorders, allergies, hypertension; Chinese Medicine in the nature of medicinal herbs; Medicinal alcohol; Pesticides; Hormones, namely, Eplerenone for treating hypertension; Fluticasone Propionate for preventing and treating allergic rhinitis; topical corticosteroid preparations, namely, diflucortolone for topical corticosteroids anti-inflammatory; Deflazacort for treating adrenal cortical hypofunction, autoimmune disease, allergic diseases and diseases of the blood system, Betamethasone for treating allergic and autoimmune inflammatory diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, and acute leukemia; Dexamethasone for treating autoimmune diseases, allergy, inflammation, asthma and ophthalmology disease; Dexamethasone for treating Inflammatory and allergic diseases; Dexamethasone sodium phosphate for treating fever, 6-methyl prednisolone for treating inflammation; steroid hormones, namely, cortisol for treating adrenal insufficiency, arthritis pauperum, rheumatic fever, arthrolithiasis, bronchial asthma, allergic dermatitis, seborrheic dermatitis, pruritus, iridocyclitis, conjunctivitis, keratitis, scleritis, tuberculous meningitis, arthritis, pleurisy, tenosynovitis, acute and chronic sprain, and tendon strain; Hydrocortisone Acetate for treating rheumatic arthritis, acute articular rheumatism, arthrolithiasis, bronchial asthma, tuberculous, purulent meningitis, tuberculous pleurisy, pyothorax, arthritis, peritendinitis, sprain, hyde's disease, and lichen planus; Medroxyprogesterone Acetate for treating algomenorrhea, functional amenorrhea, dysfunctional uterine bleeding, threatened abortion and habitual abortion, endometriosis uterine, mammary cancer, adenocarcinoma of endometrium, and renal carcinoma; Cyproterone Acetate for treating prostatic carcinoma, hirsutism, and androgenetic alopecia; Prednisolone for treating allergic and inflammatory diseases; Prednisolone Acetate for treating dermatitis, eczema, lichen planus circumscriptus, seborrheic dermatitis, rheumatism, arthritis deformans, Biett's disease, bronchial asthma, dropsical nephritis, essential thrombopenia, granulocytopenia, acute lymphatic leukemia, adrenal insufficiency, and dermatitis exfoliativa; Astenile for treating advanced cervix mature insufficiency; Trenbolone Acetate for treating chronic wasting disease, ill and frail thin, frail after operation, osteoporosis, children dysplasia, and aplastic anemia; Stanazolol for treating hereditary angioneurotic edema, and cacotrophy; Oxymetholone for treating chronic wasting disease, infirm, sick and postoperative weak thin, nausea, edema, liver dysfunction and jaundice; Estradiol for treating estrogen deficiency, metastatic breast cancer, advanced prostate cancer, acne, aleucocytosis, and postcoital contraception; Estriol for treating cervicitis, auxiliary medicine and abortion of midtrimester induction of labor, prostatauxe, prostatic carcinoma, aleucocytosis, and haemorrhage

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 23, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jun 23, 2024 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 11, 2022 INNT
GENERIC MADRID TRANSACTION SENT TO IB
May 24, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
May 23, 2022 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 28, 2022 INTR
CANCELLED SECTION 71
May 28, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 11, 2019 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 17, 2016 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 24, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 6, 2015 FICS
FINAL DISPOSITION PROCESSED
Apr 6, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 11, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 11, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2014 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2014 PUBO
NOTIFICATION PROCESSED BY IB
Aug 22, 2014 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 6, 2014 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 6, 2014 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 6, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 23, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 17, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 15, 2014 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 11, 2014 GNFN
FINAL REFUSAL E-MAILED
Jul 11, 2014 GNFR
FINAL REFUSAL WRITTEN
Jul 11, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 27, 2014 CRFA
ASSIGNED TO LIE
Jun 16, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 6, 2014 TROA
REFUSAL PROCESSED BY IB
Apr 4, 2014 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 14, 2014 RFCS
REFUSAL PROCESSED BY MPU
Mar 14, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 14, 2014 RFCR
NON-FINAL ACTION WRITTEN
Mar 13, 2014 CNRT
ASSIGNED TO EXAMINER
Mar 13, 2014 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 12, 2014 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 8, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 6, 2014 REPR